Taysha Gene Total Debt vs. Cash And Equivalents
| TSHA Stock | USD 3.08 0.16 4.94% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0048 | 0.0054 |
|
|
For Taysha Gene profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Taysha Gene to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Taysha Gene Therapies utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Taysha Gene's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Taysha Gene Therapies over time as well as its relative position and ranking within its peers.
Taysha |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Taysha Gene. If investors know Taysha will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Taysha Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.63 | Revenue Per Share 0.042 | Quarterly Revenue Growth (0.62) | Return On Assets (0.27) | Return On Equity (1.15) |
The market value of Taysha Gene Therapies is measured differently than its book value, which is the value of Taysha that is recorded on the company's balance sheet. Investors also form their own opinion of Taysha Gene's value that differs from its market value or its book value, called intrinsic value, which is Taysha Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Taysha Gene's market value can be influenced by many factors that don't directly affect Taysha Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Taysha Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Taysha Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Taysha Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Taysha Gene Therapies Cash And Equivalents vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Taysha Gene's current stock value. Our valuation model uses many indicators to compare Taysha Gene value to that of its competitors to determine the firm's financial worth. Taysha Gene Therapies is currently regarded number one company in total debt category among its peers. It is rated third in cash and equivalents category among its peers creating about 1.08 of Cash And Equivalents per Total Debt. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Taysha Gene's earnings, one of the primary drivers of an investment's value.Taysha Total Debt vs. Competition
Taysha Gene Therapies is currently regarded number one company in total debt category among its peers. Total debt of Health Care industry is at this time estimated at about 126.76 Million. Taysha Gene totals roughly 61.11 Million in total debt claiming about 48% of equities under Health Care industry.
Taysha Cash And Equivalents vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Taysha Gene |
| = | 61.11 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Taysha Gene |
| = | 66.24 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Taysha Cash And Equivalents Comparison
Taysha Gene is currently under evaluation in cash and equivalents category among its peers.
Taysha Gene Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Taysha Gene, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Taysha Gene will eventually generate negative long term returns. The profitability progress is the general direction of Taysha Gene's change in net profit over the period of time. It can combine multiple indicators of Taysha Gene, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | -72.4 M | -76.1 M | |
| Income Before Tax | -111.6 M | -117.1 M | |
| Net Loss | -157.1 M | -149.2 M | |
| Net Loss | -111.6 M | -117.1 M | |
| Income Tax Expense | 1.2 M | 1.3 M | |
| Net Interest Income | -3.7 M | -3.6 M | |
| Interest Income | 1.9 M | 1.9 M | |
| Net Loss | -214.4 M | -225.1 M | |
| Non Operating Income Net Other | -15.3 M | -16.1 M | |
| Total Other Income Expense Net | -39.1 M | -37.2 M | |
| Change To Netincome | 66.6 M | 70 M | |
| Net Loss | (0.96) | (1.01) | |
| Income Quality | 0.65 | 0.38 | |
| Net Income Per E B T | 0.92 | 0.73 |
Taysha Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Taysha Gene. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Taysha Gene position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Taysha Gene's important profitability drivers and their relationship over time.
Use Taysha Gene in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Taysha Gene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Taysha Gene will appreciate offsetting losses from the drop in the long position's value.Taysha Gene Pair Trading
Taysha Gene Therapies Pair Trading Analysis
The ability to find closely correlated positions to Taysha Gene could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Taysha Gene when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Taysha Gene - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Taysha Gene Therapies to buy it.
The correlation of Taysha Gene is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Taysha Gene moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Taysha Gene Therapies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Taysha Gene can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Taysha Gene position
In addition to having Taysha Gene in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Computers Thematic Idea Now
Computers
Companies that manufacture and distribute personal and business computers. The Computers theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Computers Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
To fully project Taysha Gene's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Taysha Gene Therapies at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Taysha Gene's income statement, its balance sheet, and the statement of cash flows.